A network propagation approach (Fig. 4B) using potential driver mutations as seeds uncovered a significant enrichment in the mutational signature of EBV + DLBCL (NOS) for immunological processes, including allograft rejection, interferon-alpha and gamma response, as well as IL6/JAK/STAT3 signaling. Here, STAT3 is linked to diffuse large B-cell lymphoma.